Drug Trial Radar · NCT03757234
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
Last checked: Nov 20, 2026Latest source record: Jul 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
201
Actual
Start
Nov 19, 2018
Primary completion
Jun 26, 2019
Study completion Jul 24, 2019
Sponsor
- Lead sponsor
- Paratek Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 28, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with acute pyelonephritis.
Conditions
- Acute Pyelonephritis
Interventions
OmadacyclineDrug
po tablets
LevofloxacinDrug
iv solution/po tablets
OmadacyclineDrug
iv solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population)Time frame: Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug).
- Number of Participants With a Microbiological Response at the PTE Visit (Micro-ITT Population)Time frame: Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug).
- Number of Participants With Resolution of All AP Signs and Clinical Symptoms at PTE Visit (ITT Population)Time frame: Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug).
- Number of Participants With No Worsening and Absence of New AP Signs and Clinical Symptoms at PTE Visit (ITT Population)Time frame: Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug).
Locations
31 sites in 4 countries. Site status is shown where the registry gives one.
Site 201
Tbilisi, Georgia
Site 202
Tbilisi, Georgia
Site 203
Tbilisi, Georgia
Site 204
Tbilisi, Georgia
Site 301
Daugavpils, Latvia
Site 304
Liepāja, Latvia
Site 305
Rēzekne, Latvia
Site 302
Riga, Latvia
Site 303
Valmiera, Latvia
Site 409
Krasnoyarsk, Russia
Site 408
Moscow, Russia
Site 410
Moscow, Russia
Site 415
Penza, Russia
Site 407
Rostov-on-Don, Russia
Site 405
Rostov-on-Don, Russia
Site 411
Saint Petersburg, Russia
Site 406
Saint Petersburg, Russia
Site 402
Saint Petersburg, Russia
Site 412
Saint Petersburg, Russia
Site 403
Saint Petersburg, Russia
Site 414
Saint Petersburg, Russia
Site 401
Saint Petersburg, Russia
Site 404
Saint Petersburg, Russia
Site 413
Smolensk, Russia
Site 502
Chernivtsi, Ukraine
Site 506
Dnipro, Ukraine
Site 505
Kharkiv, Ukraine
Site 504
Kyiv, Ukraine
Site 503
Kyiv, Ukraine
Site 501
Lviv, Ukraine
Site 507
Zaporizhzhya, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.